Skip to content
Clinical Trials – home

Thoraxklinik Heidelberg gGmbH

Verified siteinfoFast reply

Germany Roentgenstrasse 1, Rohrbach, 69126 Heidelberg, Germany

  • 46 trials recruiting
  • Non-small cell lung cancer · Pulmonary arterial hypertension · Non-small cell lung cancer metastatic
  • Adults and children

About Specializations

Thoraxklinik Heidelberg gGmbH in Heidelberg, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Pulmonary arterial hypertension, Non-small cell lung cancer metastatic, Pulmonary hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Thoraxonkologie Heidelberg - Neoplasms

Clinical research at Thoraxklinik Heidelberg gGmbH is strongly focused on cancer, especially lung cancer and related thoracic tumors. Studies are examining whether newer treatment combinations can improve survival, slow disease progression, and offer better options for patients with advanced or previously treated disease.

  • Small cell lung cancer and extensive-stage small-cell lung cancer
  • Non-Small Cell Lung Cancer (NSCLC), including metastatic and c-Met overexpressing forms
  • Pleural mesothelioma, neuroendocrine carcinoma, and other aggressive thoracic cancers

These trials are mainly testing new therapies and comparing them with current standards of care to find more effective approaches for hard-to-treat thoracic malignancies.

Respiratory Tract Diseases

The site also supports important studies in respiratory disease, with a particular emphasis on chronic and progressive lung conditions. Research here is aimed at improving breathing capacity, preserving lung function, and easing the long-term impact of serious pulmonary illness.

  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Pulmonary arterial hypertension and related forms of PAH
  • Trials assessing symptom control, exercise tolerance, and disease progression

At this Heidelberg hospital, the goal is to evaluate new treatments that may better manage debilitating lung diseases and improve day-to-day function for patients.

Cardiovascular Diseases and Pulmonary Vascular Research

Another key area of research involves pulmonary vascular disease, bridging cardiovascular and respiratory medicine. The studies are centered on pulmonary arterial hypertension, where investigators are looking for therapies that can reduce disease burden and improve physical capacity.

  • Pulmonary arterial hypertension in multiple patient groups
  • Measures of exercise ability and vascular resistance
  • Evaluation of treatment effectiveness in a chronic, high-impact condition

These trials reflect a broader effort to advance care for patients with serious cardiopulmonary disorders through better disease control and functional outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Roentgenstrasse 1, Rohrbach69126 HeidelbergGermany
Recruiting now
46 trials
Conditions studied
34
Partner status
Verified site

More sites in HeidelbergGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

134 clinical trials

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.